GSK vs NVO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Feb 02, 2026

GSK

66.5
AI Score
VS
GSK Wins

NVO

50.4
AI Score

Investment Advisor Scores

GSK

67score
Recommendation
BUY

NVO

50score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric GSK NVO Winner
Forward P/E 9.5147 16.1812 GSK
PEG Ratio 0.423 2.8381 GSK
Revenue Growth 6.7% 5.1% GSK
Earnings Growth 23.2% -26.5% GSK
Tradestie Score 66.5/100 50.4/100 GSK
Profit Margin 17.1% 32.9% NVO
Beta 1.00 1.00 Tie
AI Recommendation BUY HOLD GSK

Frequently Asked Questions

Based on our detailed analysis, GSK is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.